{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:51Z","timestamp":1792511511116,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acral melanoma (AM) has unique biology as an aggressive subtype of melanoma. It is a common subtype of melanoma in races with darker skin tones usually diagnosed at a later stage, thereby presenting a worse prognosis compared to cutaneous melanoma. The pathogenesis of acral melanoma differs from cutaneous melanoma, and trauma promotes its development. Compared to cutaneous melanomas, acral melanomas have a significantly lighter mutational burden with more copy number variants. Most acral melanomas are classified as triple wild-type. In contrast to cutaneous melanomas, acral melanomas have a suppressive immune microenvironment. Herein, we reviewed the clinical features, genetic variants, and immune microenvironmental characteristics of limbic melanomas to summarise their unique features.<\/jats:p>","DOI":"10.1186\/s12967-022-03532-2","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T12:05:27Z","timestamp":1660651527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Jianping","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-0556","authenticated-orcid":false,"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"issue":"1","key":"3532_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/pcmr.12885","volume":"34","author":"P Basurto-Lozada","year":"2021","unstructured":"Basurto-Lozada P, Molina-Aguilar C, Castaneda-Garcia C, et al. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. Pigment Cell Melanoma Res. 2021;34(1):59\u201371.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"3532_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/labinvest.2016.143","volume":"97","author":"RV Rawson","year":"2017","unstructured":"Rawson RV, Johansson PA, Hayward NK, et al. Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Lab Invest. 2017;97(2):130\u201345.","journal-title":"Lab Invest"},{"issue":"4","key":"3532_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2133.2000.03770.x","volume":"143","author":"P Kaskel","year":"2000","unstructured":"Kaskel P, Kind P, Sander S, et al. Trauma and melanoma formation: a true association? Br J Dermatol. 2000;143(4):749\u201353.","journal-title":"Br J Dermatol"},{"key":"3532_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jss.2020.02.010","volume":"251","author":"K Huang","year":"2020","unstructured":"Huang K, Fan J, Misra S. Acral lentiginous melanoma: incidence and survival in the United States, 2006\u20132015, an analysis of the SEER Registry. J Surg Res. 2020;251:329\u201339.","journal-title":"J Surg Res"},{"issue":"2","key":"3532_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/bjd.15803","volume":"178","author":"Y Teramoto","year":"2018","unstructured":"Teramoto Y, Keim U, Gesierich A, et al. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol. 2018;178(2):443\u201351.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3532_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/jdv.12141","volume":"28","author":"N Zhang","year":"2014","unstructured":"Zhang N, Wang L, Zhu GN, et al. The association between trauma and melanoma in the Chinese population: a retrospective study. J Eur Acad Dermatol Venereol. 2014;28(5):597\u2013603.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"3532_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.5021\/ad.2021.33.3.228","volume":"33","author":"JH Lee","year":"2021","unstructured":"Lee JH, Choi YD, Hwang JH, et al. Frequency of trauma, physical stress, and occupation in acral melanoma: analysis of 313 acral melanoma patients in Korea. Ann Dermatol. 2021;33(3):228\u201336.","journal-title":"Ann Dermatol"},{"issue":"6","key":"3532_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5070\/D37GC0P4N1","volume":"17","author":"S Rangwala","year":"2011","unstructured":"Rangwala S, Hunt C, Modi G, et al. Amelanotic subungual melanoma after trauma: an unusual clinical presentation. Dermatol Online J. 2011;17(6):8.","journal-title":"Dermatol Online J"},{"issue":"1","key":"3532_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2133.2006.07235.x","volume":"155","author":"G Bormann","year":"2006","unstructured":"Bormann G, Marsch WC, Haerting J, et al. Concomitant traumas influence prognosis in melanomas of the nail apparatus. Br J Dermatol. 2006;155(1):76\u201380.","journal-title":"Br J Dermatol"},{"issue":"4","key":"3532_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000063354","volume":"204","author":"M M\u00f6HRLE","year":"2002","unstructured":"M\u00f6HRLE M, H\u00e4FNER HM. Is subungual melanoma related to trauma? Dermatology. 2002;204(4):259\u201361.","journal-title":"Dermatology"},{"key":"3532_CR11","volume-title":"Subungual Melanoma","author":"RJ Mole","year":"2022","unstructured":"Mole RJ, Mackenzie DN. Subungual Melanoma. Tampa: StatPearls Publishing; 2022."},{"issue":"11","key":"3532_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1001\/jamadermatol.2013.5853","volume":"149","author":"HJ Jung","year":"2013","unstructured":"Jung HJ, Kweon SS, Lee JB, et al. A clinicopathologic analysis of 177 acral melanomas in Koreans: relevance of spreading pattern and physical stress. JAMA Dermatol. 2013;149(11):1281\u20138.","journal-title":"JAMA Dermatol"},{"key":"3532_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2021.12.001","author":"TL Lee","year":"2021","unstructured":"Lee TL, Lin MH, Liao YH, et al. Clinicopathological characteristics and prognosis in significantly thick acral lentiginous melanoma in Taiwan. J Formos Med Assoc. 2021. https:\/\/doi.org\/10.1016\/j.jfma.2021.12.001.","journal-title":"J Formos Med Assoc"},{"key":"3532_CR14","doi-asserted-by":"publisher","first-page":"31432","DOI":"10.1038\/srep31432","volume":"6","author":"J Lv","year":"2016","unstructured":"Lv J, Dai B, Kong Y, et al. Acral melanoma in Chinese: a clinicopathological and prognostic study of 142 cases. Sci Rep. 2016;6:31432. https:\/\/doi.org\/10.1038\/srep31432","journal-title":"Sci Rep"},{"issue":"9","key":"3532_CR15","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jdv.16227","volume":"34","author":"I Cs\u00e1nyi","year":"2020","unstructured":"Cs\u00e1nyi I, Houshmand N, Sz\u0171cs M, et al. Acral lentiginous melanoma: a single-centre retrospective review of four decades in East-Central Europe. J Eur Acad Dermatol Venereol. 2020;34(9):2004\u201310.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"3532_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1203475418800943","volume":"23","author":"LS Lino-silva","year":"2019","unstructured":"Lino-silva LS, Zepeda-najar C, Salcedo-hern\u00e1ndez RA, et al. Acral lentiginous melanoma: survival analysis of 715 cases. J Cutan Med Surg. 2019;23(1):38\u201343.","journal-title":"J Cutan Med Surg."},{"issue":"12","key":"3532_CR17","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1111\/ijd.15642","volume":"60","author":"L Wang","year":"2021","unstructured":"Wang L, Wu J, Dai Z, et al. Clinical characteristics and prognosis of acral lentiginous melanoma: a single-center series of 211 cases in China. Int J Dermatol. 2021;60(12):1504\u20139.","journal-title":"Int J Dermatol"},{"key":"3532_CR18","doi-asserted-by":"publisher","first-page":"5169051","DOI":"10.1155\/2020\/5169051","volume":"2020","author":"K Huang","year":"2020","unstructured":"Huang K, Xu Y, Gabriel EM, et al. Comparative analysis of acral melanoma in Chinese and Caucasian patients. J Skin Cancer. 2020;2020:5169051.","journal-title":"J Skin Cancer"},{"issue":"1","key":"3532_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1440-0960.2011.00835.x","volume":"53","author":"P Rubegni","year":"2012","unstructured":"Rubegni P, Rossi S, Nami N, et al. A single centre melanoma thickness trend (1985\u20132009) in relation to skin areas accessible and non-accessible to self-inspection. Australas J Dermatol. 2012;53(1):32\u20136.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"3532_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2133.2006.07368.x","volume":"155","author":"A Phan","year":"2006","unstructured":"Phan A, Touzet S, Dalle S, et al. Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Br J Dermatol. 2006;155(3):561\u20139.","journal-title":"Br J Dermatol"},{"key":"3532_CR21","doi-asserted-by":"publisher","first-page":"107327482110535","DOI":"10.1177\/10732748211053567","volume":"28","author":"AM Kolla","year":"2021","unstructured":"Kolla AM, Vitiello GA, Friedman EB, et al. Acral lentiginous melanoma: a United States multi-center substage survival analysis. Cancer Control. 2021;28:10732748211053568.","journal-title":"Cancer Control"},{"issue":"9","key":"3532_CR22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/ijd.12730","volume":"54","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Osella-Abate S, Ribero S, et al. Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome. Int J Dermatol. 2015;54(9):1023\u20139.","journal-title":"Int J Dermatol"},{"key":"3532_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680407","volume":"12","author":"L Mao","year":"2021","unstructured":"Mao L, Qi Z, Zhang L, et al. Immunotherapy in acral and mucosal melanoma: current status and future directions. Front Immunol. 2021;12: 680407.","journal-title":"Front Immunol"},{"issue":"5","key":"3532_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13032","volume":"32","author":"U Wollina","year":"2019","unstructured":"Wollina U, Tempel S, Hansel G. Subungual melanoma: a single center series from Dresden. Dermatol Ther. 2019;32(5): e13032.","journal-title":"Dermatol Ther"},{"issue":"6","key":"3532_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4103\/idoj.IDOJ_411_16","volume":"8","author":"A Singal","year":"2017","unstructured":"Singal A, Pandhi D, Gogoi P, et al. Subungual melanoma is not so rare: report of four cases from India. Indian Dermatol Online J. 2017;8(6):471\u20134.","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"3532_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/bjd.19406","volume":"184","author":"S Behbahani","year":"2021","unstructured":"Behbahani S, Malerba S, Samie FH. Racial and ethnic differences in the clinical presentation and outcomes of acral lentiginous melanoma. Br J Dermatol. 2021;184(1):158\u201360.","journal-title":"Br J Dermatol"},{"issue":"4","key":"3532_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","volume":"145","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Goldstein AM, McMaster ML, et al. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986\u20132005. Arch Dermatol. 2009;145(4):427\u201334.","journal-title":"Arch Dermatol"},{"key":"3532_CR28","doi-asserted-by":"publisher","DOI":"10.1159\/000522492","author":"A Gavillero","year":"2022","unstructured":"Gavillero A, Garc\u00eda-Casado Z, Requena C, et al. Differences by anatomical site of non-acral lentiginous melanomas of the lower limb. Dermatology. 2022. https:\/\/doi.org\/10.1159\/000522492.","journal-title":"Dermatology"},{"issue":"9","key":"3532_CR29","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1245\/s10434-020-08418-5.","volume":"27","author":"X Wei","year":"2020","unstructured":"Wei X, Wu D, Li H, et al. The clinicopathological and survival profiles comparison across primary sites in acral melanoma. Ann Surg Oncol. 2020;27(9):3478\u201385. https:\/\/doi.org\/10.1245\/s10434-020-08418-5.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"3532_CR30","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1111\/jdv.16193","volume":"34","author":"M Kostaki","year":"2020","unstructured":"Kostaki M, Plaka M, Stergiopoulou A, et al. Subungual melanoma: the experience of a Greek melanoma reference centre from 2003 to 2018. J Eur Acad Dermatol Venereol. 2020;34(5):e231\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"3532_CR31","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/jso.25242","volume":"118","author":"LF Nunes","year":"2018","unstructured":"Nunes LF, Mendes GLQ, Koifman RJ. Subungual melanoma: a retrospective cohort of 157 cases from Brazilian National Cancer Institute. J Surg Oncol. 2018;118(7):1142\u20139.","journal-title":"J Surg Oncol"},{"key":"3532_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1479-5876-10-192","volume":"10","author":"JB Freeman","year":"2012","unstructured":"Freeman JB, Gray ES, Millward M, et al. Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med. 2012;10:192.","journal-title":"J Transl Med"},{"issue":"22","key":"3532_CR33","doi-asserted-by":"publisher","first-page":"12416","DOI":"10.3390\/ijms222212416","volume":"22","author":"MC Rapanotti","year":"2021","unstructured":"Rapanotti MC, Cugini E, Nuccetelli M, et al. MCAM\/MUC18\/CD146 as a multifaceted warning marker of melanoma progression in liquid biopsy. Int J Mol Sci. 2021;22(22):12416.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3532_CR34","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1634\/theoncologist.2019-0557","volume":"25","author":"MA Khattak","year":"2020","unstructured":"Khattak MA, Reid A, Freeman J, et al. PD-L1 expression on circulating tumor cells may be predictive of response to pembrolizumab in advanced melanoma: results from a pilot study. Oncologist. 2020;25(3):e523.","journal-title":"Oncologist"},{"issue":"1","key":"3532_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","volume":"7","author":"A Forschner","year":"2019","unstructured":"Forschner A, Battke F, Hadaschik D, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma\u2014results of a prospective biomarker study. J Immunother Cancer. 2019;7(1):180.","journal-title":"J Immunother Cancer"},{"key":"3532_CR36","doi-asserted-by":"publisher","first-page":"11198","DOI":"10.1038\/srep11198","volume":"5","author":"SC Tsao","year":"2015","unstructured":"Tsao SC, Weiss J, Hudson C, et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep. 2015;5:11198.","journal-title":"Sci Rep"},{"issue":"3","key":"3532_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jdermsci.2021.04.006","volume":"102","author":"A Kaneko","year":"2021","unstructured":"Kaneko A, Kanemaru H, Kajihara I, et al. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients. J Dermatol Sci. 2021;102(3):158\u201366.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"3532_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-018-0886-x","volume":"17","author":"G Cesi","year":"2018","unstructured":"Cesi G, Philippidou D, Kozar I, et al. A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells. Mol Cancer. 2018;17(1):145.","journal-title":"Mol Cancer"},{"issue":"11","key":"3532_CR39","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.neo.2017.07.002","volume":"19","author":"LJ Vella","year":"2017","unstructured":"Vella LJ, Behren A, Coleman B, et al. Intercellular resistance to BRAF inhibition can be mediated by extracellular vesicle-associated PDGFR\u03b2. Neoplasia. 2017;19(11):932\u201340.","journal-title":"Neoplasia"},{"issue":"1","key":"3532_CR40","doi-asserted-by":"publisher","first-page":"1710899","DOI":"10.1080\/20013078.2019.1710899","volume":"9","author":"M Cordonnier","year":"2020","unstructured":"Cordonnier M, Nardin C, Chanteloup G, et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J Extracell Vesicles. 2020;9(1):1710899.","journal-title":"J Extracell Vesicles"},{"issue":"6","key":"3532_CR41","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3109\/1354750X.2013.816777","volume":"18","author":"E Greenberg","year":"2013","unstructured":"Greenberg E, Besser MJ, Ben-Ami E, et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 2013;18(6):502\u20138.","journal-title":"Biomarkers"},{"key":"3532_CR42","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.12659\/MSM.891327","volume":"20","author":"P Li","year":"2014","unstructured":"Li P, He QY, Luo CQ, et al. Circulating miR-221 expression level and prognosis of cutaneous malignant melanoma. Med Sci Monit. 2014;20:2472\u20137.","journal-title":"Med Sci Monit"},{"issue":"13","key":"3532_CR43","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.7150\/jca.18824","volume":"8","author":"M Bai","year":"2017","unstructured":"Bai M, Zhang H, Si L, et al. Upregulation of serum miR-10b Is associated with poor prognosis in patients with melanoma. J Cancer. 2017;8(13):2487\u201391.","journal-title":"J Cancer"},{"issue":"12","key":"3532_CR44","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1158\/1078-0432.CCR-21-3344","volume":"28","author":"Q Shi","year":"2022","unstructured":"Shi Q, Liu L, Chen J, et al. Integrative genomic profiling uncovers therapeutic targets of acral melanoma in Asian populations. Clin Cancer Res. 2022;28(12):2690\u2013703.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3532_CR45","first-page":"1968","volume":"60","author":"BC Bastian","year":"2000","unstructured":"Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 2000;60(7):1968\u201373.","journal-title":"Cancer Res"},{"issue":"1","key":"3532_CR46","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","volume":"11","author":"F Newell","year":"2020","unstructured":"Newell F, Wilmott JS, Johansson PA, et al. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020;11(1):5259.","journal-title":"Nat Commun"},{"key":"3532_CR47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejca.2019.07.008","volume":"119","author":"A Zaremba","year":"2019","unstructured":"Zaremba A, Murali R, Jansen P, et al. Clinical and genetic analysis of melanomas arising in acral sites. Eur J Cancer. 2019;119:66\u201376.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3532_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/CMR.0000000000000222","volume":"26","author":"VDEL Vazquez","year":"2016","unstructured":"Vazquez VDEL, Vicente AL, Carloni A, et al. Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. Melanoma Res. 2016;26(2):93\u20139.","journal-title":"Melanoma Res"},{"issue":"5","key":"3532_CR49","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/pcmr.12129","volume":"26","author":"HT Niu","year":"2013","unstructured":"Niu HT, Zhou QM, Wang F, et al. Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral\/mucosal melanomas. Pigment Cell Melanoma Res. 2013;26(5):646\u201353.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"3532_CR50","first-page":"7043","volume":"37","author":"G Ponti","year":"2017","unstructured":"Ponti G, Manfredini M, Greco S, et al. BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival. Anticancer Res. 2017;37(12):7043\u20138.","journal-title":"Anticancer Res"},{"issue":"10","key":"3532_CR51","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/jnci\/djz005","volume":"111","author":"I Yeh","year":"2019","unstructured":"Yeh I, Jorgenson E, Shen L, et al. Targeted genomic profiling of acral melanoma. J Natl Cancer Inst. 2019;111(10):1068\u201377.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3532_CR52","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jid.2017.08.022","volume":"138","author":"AM Haugh","year":"2018","unstructured":"Haugh AM, Zhang B, Quan VL, et al. Distinct patterns of acral melanoma based on site and relative sun exposure. J Invest Dermatol. 2018;138(2):384\u201393.","journal-title":"J Invest Dermatol"},{"issue":"25","key":"3532_CR53","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.18632\/oncotarget.27642","volume":"11","author":"A Borkowska","year":"2020","unstructured":"Borkowska A, Szumera-Cie\u0107kiewicz A, Spa\u0142ek M, et al. Mutation profile of primary subungual melanomas in Caucasians. Oncotarget. 2020;11(25):2404\u201313.","journal-title":"Oncotarget"},{"issue":"6","key":"3532_CR54","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/CMR.0000000000000688","volume":"30","author":"BN Holman","year":"2020","unstructured":"Holman BN, van Gulick RJ, Amato CM, et al. Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. Melanoma Res. 2020;30(6):562\u201373.","journal-title":"Melanoma Res"},{"issue":"8","key":"3532_CR55","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.3390\/ijms22083826","volume":"22","author":"L Elefanti","year":"2021","unstructured":"Elefanti L, Zamuner C, Fiore DELP, et al. The molecular landscape of primary acral melanoma: a multicenter study of the Italian melanoma intergroup (IMI). Int J Mol Sci. 2021;22(8):3826.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3532_CR56","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251\u201363.","journal-title":"Cell"},{"issue":"2","key":"3532_CR57","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5021\/ad.2014.26.2.195","volume":"26","author":"JW Hong","year":"2014","unstructured":"Hong JW, Lee S, Kim DC, et al. Prognostic and clinicopathologic associations of BRAF mutation in primary acral lentiginous melanoma in Korean patients: a preliminary study. Ann Dermatol. 2014;26(2):195\u2013202.","journal-title":"Ann Dermatol"},{"issue":"1","key":"3532_CR58","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","volume":"33","author":"PM Pollock","year":"2003","unstructured":"Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19\u201320.","journal-title":"Nat Genet"},{"issue":"1","key":"3532_CR59","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CMR.0000000000000091","volume":"25","author":"N Yamazaki","year":"2015","unstructured":"Yamazaki N, Tanaka R, Tsutsumida A, et al. BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res. 2015;25(1):9\u201314.","journal-title":"Melanoma Res"},{"issue":"1","key":"3532_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bjd.12939","volume":"171","author":"M Picard","year":"2014","unstructured":"Picard M, Pham Dang N, D\u2019incan M, et al. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. Br J Dermatol. 2014;171(1):108\u201314.","journal-title":"Br J Dermatol."},{"issue":"1","key":"3532_CR61","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21873\/cgp.20243","volume":"18","author":"JW Chang","year":"2021","unstructured":"Chang JW, Hsieh JJ, Wu CE, et al. Genomic landscapes of acral melanomas in East Asia. Cancer Genomics Proteomics. 2021;18(1):83\u201392.","journal-title":"Cancer Genomics Proteomics"},{"key":"3532_CR62","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.2147\/OTT.S158239","volume":"11","author":"S Yu","year":"2018","unstructured":"Yu S, Xu T, Dai J, et al. TERT copy gain predicts the outcome of high-dose interferon \u03b1-2b therapy in acral melanoma. Onco Targets Ther. 2018;11:4097\u2013104.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"3532_CR63","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/1346-8138.15841","volume":"48","author":"Y Lim","year":"2021","unstructured":"Lim Y, Lee DY. Identification of genetic mutations related to invasion and metastasis of acral melanoma via whole-exome sequencing. J Dermatol. 2021;48(7):999\u20131006.","journal-title":"J Dermatol"},{"issue":"1","key":"3532_CR64","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41467-022-28566-4","volume":"13","author":"F Farshidfar","year":"2022","unstructured":"Farshidfar F, Rhrissorrakrai K, Levovitz C, et al. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nat Commun. 2022;13(1):898.","journal-title":"Nat Commun"},{"issue":"3","key":"3532_CR65","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jaad.2018.02.019","volume":"79","author":"M Lee","year":"2018","unstructured":"Lee M, Yoon J, Chung YJ, et al. Whole-exome sequencing reveals differences between nail apparatus melanoma and acral melanoma. J Am Acad Dermatol. 2018;79(3):559-61.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3532_CR66","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.jaad.2020.03.109","volume":"83","author":"Y Lim","year":"2020","unstructured":"Lim Y, Yoon D, Lee DY. Novel mutations identified by whole-exome sequencing in acral melanoma. J Am Acad Dermatol. 2020;83(6):1792\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"22","key":"3532_CR67","doi-asserted-by":"publisher","first-page":"6946","DOI":"10.1158\/1078-0432.CCR-17-0070","volume":"23","author":"Y Kong","year":"2017","unstructured":"Kong Y, Sheng X, Wu X, et al. Frequent genetic aberrations in the CDK4 pathway in acral melanoma indicate the potential for CDK4\/6 inhibitors in targeted therapy. Clin Cancer Res. 2017;23(22):6946\u201357.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"3532_CR68","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-19-0475","volume":"25","author":"J Yu","year":"2019","unstructured":"Yu J, Yan J, Guo Q, et al. Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in chinese patients with non-cutaneous melanoma. Clin Cancer Res. 2019;25(21):6511\u201323.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3532_CR69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/pcmr.12560","volume":"30","author":"J Turner","year":"2017","unstructured":"Turner J, Couts K, Sheren J, et al. Kinase gene fusions in defined subsets of melanoma. Pigment Cell Melanoma Res. 2017;30(1):53\u201362.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"3532_CR70","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jdin.2020.07.004","volume":"1","author":"BM Tod","year":"2020","unstructured":"Tod BM, Schneider JW, Bowcock AM, et al. The tumor genetics of acral melanoma: what should a dermatologist know? JAAD Int. 2020;1(2):135\u201347.","journal-title":"JAAD Int"},{"issue":"11","key":"3532_CR71","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1158\/2326-6066.CIR-19-0835","volume":"8","author":"J Edwards","year":"2020","unstructured":"Edwards J, Ferguson PM, Lo SN, et al. Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas. Cancer Immunol Res. 2020;8(11):1346\u201353.","journal-title":"Cancer Immunol Res"},{"key":"3532_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.604213","volume":"10","author":"DG Trembath","year":"2020","unstructured":"Trembath DG, Davis ES, Rao S, et al. Brain tumor microenvironment and angiogenesis in melanoma brain metastases. Front Oncol. 2020;10: 604213.","journal-title":"Front Oncol"},{"issue":"3","key":"3532_CR73","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/pcmr.12926","volume":"34","author":"GH Attrill","year":"2021","unstructured":"Attrill GH, Ferguson PM, Palendira U, et al. The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell Melanoma Res. 2021;34(3):529\u201349.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"3532_CR74","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1158\/0008-5472.CAN-11-3218","volume":"72","author":"G Erdag","year":"2012","unstructured":"Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72(5):1070\u201380.","journal-title":"Cancer Res"},{"issue":"7","key":"3532_CR75","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/jcm10071452","volume":"10","author":"AM Borkowska","year":"2021","unstructured":"Borkowska AM, Szumera-Cie\u0107kiewicz A, Chraszczewska M, et al. Clinical significance of tumor microenvironment in acral melanoma: a large single-institution study of Caucasians. J Clin Med. 2021;10(7):1452.","journal-title":"J Clin Med"},{"issue":"9","key":"3532_CR76","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s12094-019-02033-x","volume":"21","author":"CA Castaneda","year":"2019","unstructured":"Castaneda CA, Castillo M, Torres-Cabala C, et al. Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. Clin Transl Oncol. 2019;21(9):1127\u201334.","journal-title":"Clin Transl Oncol"},{"issue":"12","key":"3532_CR77","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1007\/s12094-017-1685-3","volume":"19","author":"CA Castaneda","year":"2017","unstructured":"Castaneda CA, Torres-Cabala C, Castillo M, et al. Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clin Transl Oncol. 2017;19(12):1478\u201388.","journal-title":"Clin Transl Oncol"},{"issue":"21","key":"3532_CR78","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.30259","volume":"122","author":"AN Shoushtari","year":"2016","unstructured":"Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122(21):3354\u201362.","journal-title":"Cancer"},{"issue":"9","key":"3532_CR79","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.annonc.2020.05.031","volume":"31","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Namikawa K, Yoshino K, et al. Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients. Ann Oncol. 2020;31(9):1198\u2013206.","journal-title":"Ann Oncol"},{"issue":"10","key":"3532_CR80","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-21-3145","volume":"28","author":"J Li","year":"2022","unstructured":"Li J, Smalley I, Chen Z, et al. Single-cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy. Clin Cancer Res. 2022;28(10):2131\u201346.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3532_CR81","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/CMR.0000000000000449","volume":"28","author":"WJ Lee","year":"2018","unstructured":"Lee WJ, Lee YJ, Shin HJ, et al. Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes. Melanoma Res. 2018;28(5):423\u201334.","journal-title":"Melanoma Res"},{"issue":"3","key":"3532_CR82","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4132\/jptm.2018.04.04","volume":"52","author":"HA Usman","year":"2018","unstructured":"Usman HA, Hernowo BS, Tobing MDL, et al. The major role of NF-\u03baB in the depth of invasion on acral melanoma by decreasing CD8(+) T cells. J Pathol Transl Med. 2018;52(3):164\u201370.","journal-title":"J Pathol Transl Med"},{"key":"3532_CR83","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2147\/CCID.S334984","volume":"14","author":"FAZ Abidin","year":"2021","unstructured":"Abidin FAZ, Usman HA, Suryanti S, et al. CD103+ T lymphocyte count linked to the thickness of invasion on acral melanoma without E-cadherin involvement. Clin Cosmet Investig Dermatol. 2021;14:1783\u201390.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"3532_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.524700","volume":"10","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Zhenjie Z, Oya K, et al. Poor lymphocyte infiltration to primary tumors in acral lentiginous melanoma and mucosal melanoma compared to cutaneous melanoma. Front Oncol. 2020;10: 524700.","journal-title":"Front Oncol"},{"issue":"7","key":"3532_CR85","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/his.13478","volume":"72","author":"M Z\u00fa\u00f1iga-Castillo","year":"2018","unstructured":"Z\u00fa\u00f1iga-Castillo M, Pereira NV, Sotto MN. High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma. Histopathology. 2018;72(7):1189\u201398.","journal-title":"Histopathology"},{"issue":"9","key":"3532_CR86","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/pin.12440","volume":"66","author":"M Takeya","year":"2016","unstructured":"Takeya M, Komohara Y. Role of tumor-associated macrophages in human malignancies: friend or foe? Pathol Int. 2016;66(9):491\u2013505.","journal-title":"Pathol Int"},{"issue":"1","key":"3532_CR87","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","volume":"6","author":"VS Maleki","year":"2018","unstructured":"Maleki VS. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157.","journal-title":"J Immunother Cancer."},{"issue":"4","key":"3532_CR88","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847\u201356.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3532_CR89","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"3532_CR90","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.7150\/jca.30573","volume":"10","author":"S Yun","year":"2019","unstructured":"Yun S, Park Y, Moon S, et al. Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. J Cancer. 2019;10(13):3070\u20138.","journal-title":"J Cancer"},{"issue":"3","key":"3532_CR91","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/his.13527","volume":"73","author":"M Ren","year":"2018","unstructured":"Ren M, Dai B, Kong YY, et al. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients. Histopathology. 2018;73(3):386\u201396.","journal-title":"Histopathology"},{"issue":"9","key":"3532_CR92","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","volume":"97","author":"GJ Kaunitz","year":"2017","unstructured":"Kaunitz GJ, Cottrell TR, Lilo M, et al. Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Invest. 2017;97(9):1063\u201371.","journal-title":"Lab Invest"},{"issue":"5","key":"3532_CR93","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/bjd.19211","volume":"183","author":"S Behbahani","year":"2020","unstructured":"Behbahani S, Malerba S, Samie FH. Acral lentiginous melanoma: clinicopathological characteristics and survival outcomes in the US National Cancer Database 2004\u20132016. Br J Dermatol. 2020;183(5):952\u20134.","journal-title":"Br J Dermatol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03532-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03532-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T23:58:40Z","timestamp":1676419120000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03532-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3532"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03532-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest that are directly relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"367"}}